Media Mentions
2012
“McDermott Launches in Turkey via Fora & Sanli Link-Up”
The Lawyer (UK), January 4, 2012
John Callahan discussed the Firm's new relationship with Istanbul-based Fora & Sanli and the work the two firms will be doing together on health-focused M&A. The Turkish healthcare sector is currently of interest to foreign and domestic investors, who are taking advantage of opportunities presented through leveraged buy-outs and PPP deals.
“McDermott Secures Turkey Launch as Firm Targets Healthcare M&A Work”
Legal Week (UK), January 3, 2012
John Callahan said that McDermott will “fill the void that currently exists in Turkey for qualified, health-focused M&A expertise” by setting up a preferred provider relationship with Istanbul’s Fora & Sanli. The two firms will work with international clients on health sector transactions in Turkey and the surrounding region.
2010
“Mergers Between Insurers and Hospitals Expected to Accelerate”
American Medical News, October 25, 2010,
“The Tension in Hospital-Insurer Acquisition Talk”
Nashville Post, October 26, 2010
John Callahan said of health sector mergers that “health care reform policies are driving consolidation, and at the same time antitrust enforcement is scrutinizing consolidation.” He sees consolidation driven by pressure on hospitals and physicians to make reform-related investments, stating, “Not only do you have to provide a higher quality service, you have to be able to prove that you did so. Right now hospitals don’t have the infrastructure to meet those reporting requirements, and certainly very few physicians offices do.”
"Proton pros and cons | Some cite dearth of studies on effectiveness; others see therapy's unique value"
Modern Healthcare, September 27, 2010
John Callahan discussed proton therapy centers, which may offer more precise tumor irradiation than traditional radiation therapy. Mr. Callahan said that, despite the cost of creating such facilities, "when a healthcare center is looking at making this investment they're looking at whether one of their competitors will do it first, so it motivates them to move to get the competitive advantage." He added that there are other benefits for providers, who "can brand the proton center and that gives them the ability to offer a service that their competitors can't and possibly get a National Cancer Institute designation. With that can come research funds." If hospitals can find investors to share the cost, Mr. Callahan added, "Now the hospital has to ask, 'Is this the best way to spend $20 million?'"
John Callahan was quoted by Dow Jones Private Equity Analyst on June 2 concerning the likelihood that the health care reform law will create new opportunities in the health sector for buyout and venture firms. For example, he noted, proposed but yet undefined reimbursement cuts may make organizations like smaller specialty hospitals targets for consolidation by private equity firms. “No matter how you slice it, there will be an opportunity to do roll-ups,” Mr. Callahan said.
2008
John M. Callahan was mentioned in a press release published by Business Wire regarding McDermott's legal counsel to EyeCyte, Inc. in the company's Series A funding through an agreement with Pfizer. Under the terms of the deal, Pfizer has invested $3 million in Series A Preferred shares of EyeCyte, a company that believes to have developed a way to isolate and use stem cells to cure macular degeneration, retinopathy and other leading causes of blindness in the world. Mr. Callahan provided legal services to EyeCyte supporting this arrangement.
John M. Callahan, Health, Life Sciences & Medical Products Litigation, Life Sciences - Health
John M. Callahan was mentioned in the June 23 issue of Forbes.com regarding McDermott’s legal counsel to EyeCyte, Inc. in the company’s Series A funding through an agreement with Pfizer. Under the terms of the deal, Pfizer has invested $3 million in Series A Preferred shares of EyeCyte, a company that believes to have developed a way to isolate and use stem cells to cure macular degeneration, retinopathy and other leading causes of blindness in the world. Mr. Callahan provided legal services to EyeCyte supporting this arrangement.
John M. Callahan, Health, Life Sciences & Medical Products, Life Sciences - Health
John M. Callahan was mentioned in the June 23 issue of PR-inside.com regarding McDermott’s legal counsel to EyeCyte, Inc. in the company’s Series A funding through an agreement with Pfizer. Under the terms of the deal, Pfizer has invested $3 million in Series A Preferred shares of EyeCyte, a company that believes to have developed a way to isolate and use stem cells to cure macular degeneration, retinopathy and other leading causes of blindness in the world. Mr. Callahan provided legal services to EyeCyte supporting this arrangement.
John M. Callahan, Health, Life Sciences & Medical Products, Life Sciences - Health
2007
John Callahan was quoted in the June 14 issue of Muskogee Phoenix in an article regarding the Muskogee Medical Center Authority asking the state attorney general for his opinion before giving millions to the city of Muskogee. Capella Healthcare is paying $120 million to lease Muskogee Regional Medical Center for the next 40 years. “It sounds like you don’t have a decision where the money is going to go. The attorney general may be very concerned with that. You should probably have that decided before you contact him,” Mr. Callahan said.
John M. Callahan, Health, Health - M&A, Life Sciences - Health
2005
John Callahan was quoted in the Summer 2005 issue of Outsourcing Essentials in the article "What critical factors must a company take into consideration when deciding which law firm to hire?" Mr. Callahan said companies must look for experienced lawyers when considering an outsourcing transaction. "Recognizing the complexity of most outsourcing contracts, it makes sense to hire legal advisors who have developed an expertise in negotiating the agreements typically used to outsource services. Lawyers who specialize in outsourcing are accustomed to reviewing outsourcing agreements, know how to cut through the morass of text and get to the heart of what is important. This includes negotiating meaningful performance standards."
